Firms

Osage University Partners

Bala Cynwyd, Pennsylvania, US

oup.vc

signal.nfx.com

goldi.ai

Osage University Partners (OUP) is a venture capital firm that invests in science-driven startups emerging from the world's leading research labs and innovation ecosystems. Founded in 2009 and headquartered in Bala Cynwyd, Pennsylvania, OUP manages over $800 million and has invested in more than 150 life science and technology startups.

Founded: —
Type: Venture capital

Funds4

Penn-BioNTech Innovative Therapeutics Seed Fund
Announced 2026-01-09
PxB Fund: USD 50m launch 2026-01-09, Penn release published 2026-01-13. OUP-managed specialized Penn/BioNTech vehicle, seed/Series A; formal final-close status not specified. Not OUP V or automatic AUM increase.
—
OUP IV
Announced 2023
Official approach says fourth fund launched 2023. SEC amendment signed 2023-04-04 aggregates OUP IV plus OUP IV AFF Partnership: USD 275m offering and USD 195825000 sold, first sale 2022-04-08. Aggregated regulatory figures are not individual final-close fund amount.
—
OUP III
Announced 2019-03-12
USD 273m final close announced 2019-03-12, exceeded USD 250m target. Historical approximately USD 600m AUM not fund amount.
$273M
OUP II
Announced 2015
Historical USD 215m closed in 2015, recalled by firm 2019-03-12 release; exact day unknown.
$215M

Team

Investments

team@apexlogos.ai11 minutes ago
Investment-fund research reviewed 2026-10-06. Publicly identified funds, dates, amounts and fundraising status are below. Undisclosed commitments remain unknown; this is not a complete register of private SPVs or parallel entities. Fund size, vintage and status All amounts below are US dollars. AUM, flagship funds, specialized funds and company financing rounds are different measures. | Vehicle/measure | Supported amount and date | Status and interpretation | Supporting source | | --- | --- | --- | --- | | OUP aggregate AUM | Approximately **$800M**, official page accessed 2026-10-06 | Aggregate managed assets, not one fund. No audited as-of date on page; do not label it a current flagship fund size. | [OUP approach, undated](https://oup.vc/approach/) | | OUP IV plus OUP IV AFF Partnership | **$275M offering**, **$195.825M sold** as of amendment signed **2023-04-04**; first sale **2022-04-08** | SEC filing aggregates both issuers. Sold amount is a filing-time fundraising disclosure, not proof of final close. Official site calls fourth fund launched in 2023. Formation, first sale and launch dates serve different purposes. Final flagship IV close size not verified. | [SEC Form D/A](https://www.sec.gov/Archives/edgar/data/1901483/000190148323000001/xslFormDX08/primary_doc.xml) | | OUP III | **$273M closed**, announced **2019-03-12**, exceeding **$250M target** | Verified historical final close; announcement put OUP AUM at approximately $600M then. | [Firm Business Wire release reproduced by MarketScreener](https://www.marketscreener.com/news/latest/Osage-University-Partners-Closes-Oversubscribed-273-Million-Third-Venture-Fund-for-University-Sta-28152224/); [Crunchbase News, 2019-03-13](https://news.crunchbase.com/venture/osage-university-partners-raises-third-fund-for-university-research-spinouts/) | | OUP II | **$215M closed in 2015** | Historical fund size recalled in the 2019 firm announcement; not current fund. | [2019 firm announcement](https://www.marketscreener.com/news/latest/Osage-University-Partners-Closes-Oversubscribed-273-Million-Third-Venture-Fund-for-University-Sta-28152224/) | | Penn-BioNTech Innovative Therapeutics Seed Fund / PxB Fund | **$50M launched 2026-01-09** | Separate Penn-origin life-science vehicle managed by OUP, with Penn and BioNTech. Official sources say launched, rather than specifying a final-close fundraising status. Do not call it OUP V or add $50M to AUM without reconciliation. | [PxB official website, dated launch statement](https://www.pxbfund.com/); [Penn research office, 2026-01-13](https://research.upenn.edu/news/penn-and-biontech-launch-50-million-fund-to-accelerate-life-sciences-innovation/) | Searches for newer flagship funds did not verify OUP V or a later final close of OUP IV. **Latest-known flagship: IV; newer specialized launch: PxB.** The $350M in Signal search-index material and the $800M “Fund Size” label on [Goldilocks, updated 2026-09-09](https://goldi.ai/intelligence/vc/osage-university-partners) are unsuitable substitutes for a confirmed final-close amount. Goldilocks' description uses $800M as managed assets; its field label conflates AUM with a fund. Funds recorded in Adex after this review: | Fund | Disclosed amount | Announcement / filing date | | --- | --- | --- | | OUP II | USD 215000000 | 2015 | | OUP III | USD 273000000 | 2019-03-12 | | OUP IV | Undisclosed / unverified | 2023 | | Penn-BioNTech Innovative Therapeutics Seed Fund | Undisclosed / unverified | 2026-01-09 |
team@apexlogos.ai1 hour ago
Match research 2026-10-06 / GoldiOsageUniversityPartners / sha256:177e26d612ffbb32746b6b8e6ab1e813698f3a78900dbf2d2b7dc9002e24414c / part 2 of 2 Imported completed research. Baseline Adex/Signal statements describe prior state, not independent verification. Retain cited attribution, date, currency and classification caveats. | **IonQ** | Quantum computing systems and qubit technology; physical computing research commercialization, not general AI/SaaS. | Company names OUP as an existing investor participating in **$55M financing**, **2019-10-22**, led by Samsung Catalyst Fund and Mubadala. Release does not label the round Series B, so no stage label inferred from aggregators. | [IonQ-issued GlobeNewswire announcement, 2019-10-22](https://www.globenewswire.com/news-release/2019/10/22/1933078/0/en/IonQ-Secures-55-Million-in-Funding-to-Bring-Quantum-Computing-from-the-Lab-to-the-Enterprise.html); [OUP Marc Singer biography, undated](https://oup.vc/team/marc-singer/) | | **Metalenz** | Metasurface optics, high-performance 3D and polarization sensing; photonics/nanostructured optics. | OUP named participant in **$30M Series B closed**, **2022-10-12**, led by Neotribe Ventures. | [Metalenz official announcement, 2022-10-12](https://metalenz.com/metalenz-raises-30-million-series-b-led-by-neotribe-ventures/); [transaction counsel Latham & Watkins, 2022-10-14](https://www.lw.com/en/news/2022/10/latham-advises-metalenz-million-series-b-financing) | | **NuMat / Numat Technologies** | Molecularly engineered metal-organic frameworks for gas storage, separation and purification; materials chemistry and manufacturing. | OUP named participant in **$12.4M financing**, announced **2018-04-26**, led by OS Fund. Round stage not reliably established; do not adopt aggregator Series B automatically. | [NuMat-issued Business Wire release reproduced by MarketScreener, 2018-04-26](https://www.marketscreener.com/news/latest/NuMat-Technologies-Closes-12-4M-Funding-Round-to-Accelerate-Commercialization-of-Molecularly-Engine-26433792/); [Chemical & Engineering News, 2018-05-06](https://cen.acs.org/business/start-ups/NuMat-raises-124-million-commercialize/96/i19) | OUP's official team biographies also explicitly identify **SiFive**, **Everactive**, **Verdox**, **Brimstone** and others as investment examples. They are additional semiconductor, sensor and climate-technology leads, rather than fully researched round records in this file. [Manny Stockman biography, undated](https://oup.vc/team/manny-stockman/); [Marc Singer biography, undated](https://oup.vc/team/marc-singer/). Ordinary enterprise software names were not automatically labeled deep tech. ## Named previous neurotech investments | Company | Neural/brain technology and classification | Firm attribution and round/date | Sources | | --- | --- | --- | --- | | **MicroTransponder**, later presented as **Mobia Medical** | **Direct neurotechnology**: implanted Vivistim paired vagus nerve stimulation used with stroke rehabilitation to engage neuroplasticity. This is neuromodulation, not a brain-computer interface. | OUP explicitly joined **$53M Series E**, announced **2022-06-20**, with Bill Harrington joining the board. Same Series E subsequently finalized at **$73M**, reported **2022-09-22**; do not count $53M plus $73M as independent rounds. | [Company-issued PR Newswire announcement, 2022-06-20](https://www.prnewswire.com/news-releases/microtransponder-raises-53m-appoints-new-ceo-301571087.html); [Fierce Biotech, 2022-09-22](https://www.fiercebiotech.com/medtech/microtransponder-maxes-out-financing-73m-stroke-rehab-neurostim-device) | | **Neuros Medical / Neuros** | **Direct neurotechnology, peripheral rather than cortical**: Altius nerve cuff and implantable pulse generator inhibit damaged peripheral-nerve pain signaling in amputees. | OUP explicitly named existing investor in **$56M Series D**, **2025-07-09**, led by EQT Life Sciences. Official OUP biography independently calls Neuros an OUP portfolio company. | [Neuros-issued release hosted by co-investor Sectoral, 2025-07-09](https://www.sectoral.com/PDF/PE%20News/Neuros_News_2025-07-09.pdf); [MassDevice, 2025-07-09](https://www.massdevice.com/neuros-medical-raises-56m-series-d-to-support-nerve-stim-tech/); [OUP Bill Harrington biography, undated](https://oup.vc/team/bill-harrington/) | **MicroTransponder/Mobia update:** OUP's current Bill Harrington biography lists Mobia Medical; [Mobia investor-relations S-1/A, filed 2026-05-04](https://ir.mobia.com/static-files/77614b9e-2e5c-4776-b3e4-1869b92682a2) explicitly identifies OUP III and OUP IV as holders of Series F shares and documents OUP-affiliated convertible notes. This corroborates continued firm attribution. A [2025 company-release URL](https://www.prnewswire.com/news-releases/microtransponder-secures-65-million-to-enhance-vivistim-adoption-for-chronic-stroke-recovery-302400062.html) and search-index reporting indicate a $65M Series F in March 2025, but its full body was not consistently retrievable in this session (direct retrieval returned HTTP 403). Treat that exact announcement date/round investor roster as a review lead, not a fully extracted funding record here. **Adjacent neuroscience examples:** Aptinyx is an OUP-backed company per the [official February 19, 2020 promotion announcement](https://portal.oup.vc/news/489877/Osage-University-Partners-Promotes-Kirsten-Leute-to-Partner.htm), and the snapshot provides neurological-drug funding announcements. Neuroscience therapeutics are distinct from devices that directly stimulate/record nerves. Aptinyx, E-Scape Bio, Biohaven and migraine medicines should not be merged into the direct-neuromodulation examples above without specific classification and round verification. No verified cortical BCI investment was identified in the focused sources checked; that does not establish portfolio absence. ## Conflicts, gaps and concrete Adex review notes 1. Preserve the exact ID and canonical name **Osage University Partners**. Distinguish OUP from Osage Venture Partners and umbrella Osage Partners; the official footer calls OVP a sister fund. 2. Keep $800M as approximate AUM, $273M as historical closed OUP III, and $275M as a 2023 OUP IV offering amount. IV's final close remains missing. Record the newer $50M PxB launch separately, with seed/Series A strategy and OUP management attribution. 3. Reconcile duplicate snapshot company names: **Neuros/Neuros Medical**, **Terremoto/Terremoto Biosciences**, **Delfi/Delfi Diagnostics**, **Kate/Kate Therapeutics** and others. Snapshot row count is not a unique investment count. 4. Resolve **MicroTransponder/Mobia Medical** as a company-name continuity question before creating a separate investment. Consolidate the $53M and $73M Series E entries as initial/final closing of one round. SEC/IR evidence supports continued OUP III/IV involvement, but exact 2025 funding details warrant direct release review. 5. Investigate AGTC's `2003` snapshot participation date: it precedes OUP's 2009 founding. A partner's former-firm investment cannot be attributed to OUP without firm-level evidence. Harrington joined OUP in 2012 after Three Arch; his [official biography](https://oup.vc/team/bill-harrington/) explains that history. 6. Signal's $350M search-index fund field, older Principal title, gated investment list and implausible merged experience entries are not suitable authoritative update inputs. Firm check-size limits remain unverified despite $5M–$10M personal profile ranges. 7. Official portfolio webpage's accessible text lacks the full dynamic company roster. This research verifies selected high-relevance examples using individual primary announcements; it does not audit every portfolio company, every baseline investment, ownership percentage, current holdings or exit outcome. 8. Undated webpages are dated by access (**2026-10-06**), not assumed publication date. PR Newswire pages were intermittently inaccessible; a co-investor-hosted company release and reputable trade reporting were used for Neuros. All sources above were accessed 2026-10-06. No database update, MCP Patch or commit was performed.
team@apexlogos.ai1 hour ago
Match research 2026-10-06 / GoldiOsageUniversityPartners / sha256:177e26d612ffbb32746b6b8e6ab1e813698f3a78900dbf2d2b7dc9002e24414c / part 1 of 2 Imported completed research. Baseline Adex/Signal statements describe prior state, not independent verification. Retain cited attribution, date, currency and classification caveats. # Osage University Partners - Exact Adex ID: `GoldiOsageUniversityPartners` - Canonical Adex page: https://adex.page/firms/GoldiOsageUniversityPartners - Official website: https://oup.vc/ - Research date and source access date: **2026-10-06** - Status: research complete for the requested fields; unresolved items are explicitly identified below. Research only; no Adex/database changes. ## Identity and conclusion Osage University Partners (OUP) is the research commercialization venture firm established in 2009, based in Bala Cynwyd in the Philadelphia area. The `Goldi` prefix is part of the existing exact Adex ID, not the firm's operating name. OUP is distinct from its sister fund **Osage Venture Partners**, whose software-oriented strategy and fund history must not be merged into this record. OUP's official approach page supports a science/deep-technology mandate, approximately **US$800 million AUM**, and investment from its **fourth flagship fund launched in 2023**. This is a strong deep-tech match, with verified direct neurotechnology investments in **MicroTransponder/Vivistim** and **Neuros Medical/Altius**. [Official approach, undated](https://oup.vc/approach/). ## Starting evidence: saved Adex and NFX Signal The exact-ID saved Adex snapshot, `data/research/_sources/GoldiOsageUniversityPartners.adex.json`, was retrieved on 2026-10-06 at 19:29:05 UTC through read-only Search. Its matching firm record describes OUP as founded in 2009, with over $800M managed and more than 150 startups backed; it links the official site, Signal and Goldilocks. Check minimum, maximum and sweet spot are null. The matching record contains **110 investment participation rows**, including repeated companies/rounds, and 21 role rows. These are starting claims, not independently validated transactions. Examples relevant here are Neuros Medical, MicroTransponder, Quantum Circuits, NuMat and Aptinyx. The snapshot's date `2003` for AGTC precedes OUP's founding and requires correction or attribution investigation before reuse. The linked [NFX firm page](https://signal.nfx.com/firms/osage-university-partners) was directly read. It gives founding year 2009 and Philadelphia/Cambridge locations and co-investor links; the accessible rendering did not provide a reliable firm-wide fund amount or a populated team roster. [Manny Stockman's Signal profile](https://signal.nfx.com/investors/manny-stockman) and [Bill Harrington's profile](https://signal.nfx.com/investors/bill-harrington) directly show $5M–$10M investment ranges and $7.5M sweet spots. These are investor-profile claims, not independently verified current firm check limits. Harrington's page gates investment details behind sign-in; search-index material surfaced Neuros and Mobia/MicroTransponder rounds, which were investigated separately. [Anurag Agarwal's Signal profile](https://signal.nfx.com/investors/anurag-agarwal) was also directly inspected. Its live rendering calls him Partner and gives the same check range, while earlier search-index content called him Principal and reported a $350M “current fund size.” That amount is not confirmed by official fund evidence. The page also contains implausible Hotmail experience entries, demonstrating why identity/role/fund claims require corroboration. All Signal pages are undated and were accessed 2026-10-06. ## Fund size, vintage and status All amounts below are US dollars. AUM, flagship funds, specialized funds and company financing rounds are different measures. | Vehicle/measure | Supported amount and date | Status and interpretation | Supporting source | | --- | --- | --- | --- | | OUP aggregate AUM | Approximately **$800M**, official page accessed 2026-10-06 | Aggregate managed assets, not one fund. No audited as-of date on page; do not label it a current flagship fund size. | [OUP approach, undated](https://oup.vc/approach/) | | OUP IV plus OUP IV AFF Partnership | **$275M offering**, **$195.825M sold** as of amendment signed **2023-04-04**; first sale **2022-04-08** | SEC filing aggregates both issuers. Sold amount is a filing-time fundraising disclosure, not proof of final close. Official site calls fourth fund launched in 2023. Formation, first sale and launch dates serve different purposes. Final flagship IV close size not verified. | [SEC Form D/A](https://www.sec.gov/Archives/edgar/data/1901483/000190148323000001/xslFormDX08/primary_doc.xml) | | OUP III | **$273M closed**, announced **2019-03-12**, exceeding **$250M target** | Verified historical final close; announcement put OUP AUM at approximately $600M then. | [Firm Business Wire release reproduced by MarketScreener](https://www.marketscreener.com/news/latest/Osage-University-Partners-Closes-Oversubscribed-273-Million-Third-Venture-Fund-for-University-Sta-28152224/); [Crunchbase News, 2019-03-13](https://news.crunchbase.com/venture/osage-university-partners-raises-third-fund-for-university-research-spinouts/) | | OUP II | **$215M closed in 2015** | Historical fund size recalled in the 2019 firm announcement; not current fund. | [2019 firm announcement](https://www.marketscreener.com/news/latest/Osage-University-Partners-Closes-Oversubscribed-273-Million-Third-Venture-Fund-for-University-Sta-28152224/) | | Penn-BioNTech Innovative Therapeutics Seed Fund / PxB Fund | **$50M launched 2026-01-09** | Separate Penn-origin life-science vehicle managed by OUP, with Penn and BioNTech. Official sources say launched, rather than specifying a final-close fundraising status. Do not call it OUP V or add $50M to AUM without reconciliation. | [PxB official website, dated launch statement](https://www.pxbfund.com/); [Penn research office, 2026-01-13](https://research.upenn.edu/news/penn-and-biontech-launch-50-million-fund-to-accelerate-life-sciences-innovation/) | Searches for newer flagship funds did not verify OUP V or a later final close of OUP IV. **Latest-known flagship: IV; newer specialized launch: PxB.** The $350M in Signal search-index material and the $800M “Fund Size” label on [Goldilocks, updated 2026-09-09](https://goldi.ai/intelligence/vc/osage-university-partners) are unsuitable substitutes for a confirmed final-close amount. Goldilocks' description uses $800M as managed assets; its field label conflates AUM with a fund. ## Investment stages and mandate The current official approach emphasizes research-originated companies and meaningful capital reserved for follow-on rounds, but does not enumerate a current flagship stage boundary. The **2019 OUP III announcement explicitly spans seed through late stage/pre-IPO**, across life sciences and technology; this is historical fund-specific strategy. Verified historical transactions below show Series B and late-stage Series D/E participation. A late follow-on round does not prove that OUP entered a company only at that stage. [2019 fund release](https://www.marketscreener.com/news/latest/Osage-University-Partners-Closes-Oversubscribed-273-Million-Third-Venture-Fund-for-University-Sta-28152224/). **PxB's current stated mandate is seed and Series A** for Penn-derived therapeutics, diagnostics, research platforms/tools and other life-science technologies, with approximately 15 companies expected in the early years. This focused mandate should be kept separate from OUP's broader flagship strategy. [Penn research office, 2026-01-13](https://research.upenn.edu/news/penn-and-biontech-launch-50-million-fund-to-accelerate-life-sciences-innovation/). ## Named previous deep-tech investments The following are verified examples, not an exhaustive portfolio. Round amounts are total company rounds; **OUP's individual checks are undisclosed** in these sources. | Company | Technology rationale | Firm attribution and supported round/date | Sources | | --- | --- | --- | --- | | **Quantum Circuits** | Yale-origin superconducting quantum computing, including qubits with built-in error detection; hardware/scientific deep tech. | OUP explicitly named among participants in **more than $60M final Series B**, **2024-08-15**. Other investors led; do not mark OUP lead. | [Company announcement, publication date not displayed](https://quantumcircuits.com/resources/quantum-circuits-secures-series-b-investment/); [company-issued dated PR Newswire release, 2024-08-15](https://www.prnewswire.com/news-releases/quantum-circuits-secures-more-than-60-million-in-series-b-investment-302221428.html) |
team@apexlogos.ai22 days ago
MATCH

Ajay Rayasam Osage University Partners, principal	$7M$5M – $10M	Cambridge, Massachusetts
Marc Singer Osage University Partners, managing_partner	$7M$5M – $10M	Philadelphia, Pennsylvania
Robert Adelson Osage University Partners, managing_partner	$7M$5M – $10M	Philadelphia, Pennsylvania
Allen Chen Osage University Partners, Principal	—— – —
Anna Turetsky Osage University Partners, General Partner, PxB Fund	—— – —
Beth Grafstrom Osage University Partners, Senior Vice President	—— – —
Bill Harrington Osage University Partners, Managing Partner	—— – —
Britt Kennett Osage University Partners, Senior Executive Assistant	—— – —
Brittany de Kouchkovsky Osage University Partners, Director, University Relations	—— – —
Chris Nawalinski Osage University Partners, Fund Accountant	—— – —
Claudia Dunnous Osage University Partners, Chief Financial Officer	—— – —
Justin Robeny Osage University Partners, Associate	—— – —
Kayti Mangels Osage University Partners, Executive Assistant and Program Coordinator	—— – —
Kirsten Leute Osage University Partners, Partner	—— – —
Kumar Patel Osage University Partners, Fund Controller	—— – —
Louis Berneman Osage University Partners, Founding Partner	—— – —
Manny Stockman Osage University Partners, Managing Partner	—— – —
Matt Cohen Osage University Partners, Managing Partner	—— – —
Mitra Miri Osage University Partners, Partner	—— – —
Nabil Ullah Osage University Partners, Associate	—— – —
Sami Nabil Osage University Partners, Analyst	—— – —

$108M2026-04-15	Terremoto	Osage University Partners
$63M2026-01-12	Precede Biosciences	Osage University Partners
$100M2025-12-17	Addition Therapeutics	Osage University Partners
$56M2025-07-09	Neuros	Osage University Partners
$56M2025-07-09	Neuros Medical	Osage University Partners
$150M2025-04-02	Atsena Therapeutics	Osage University Partners
$—2025-01-13	Overland AI	8VC, Osage University Partners
$150M2025	Atsena Therapeutics	Osage University Partners
$56M2025	Neuros	Osage University Partners
$—2024-08-15	Quantum Circuits	Osage University Partners
$11M2024-03-14	Quintessent	Osage University Partners
$57M2023-10-10	Precede Biosciences	Osage University Partners
$51M2023-06-08	Kate	Osage University Partners
$135M2023-03-01	Chroma Medicine	ARCH Venture Partners, Casdin Capital, Atlas Venture, DCVC, Wellington Management, Cormorant Asset Management, Osage University Partners
$55M2023-01-11	Hack The Box	Osage University Partners
$51M2023-01-05	Opsys	Osage University Partners
$30M2022-10-12	Metalenz	Osage University Partners
$73M2022-09-21	MicroTransponder	Osage University Partners
$—2022-07-18	Delfi	Osage University Partners
$73M2022-06-20	MicroTransponder	Osage University Partners
$225M2022	Delfi	Osage University Partners
$75M2021-09-02	Corelight	General Catalyst, Gaingels, Accel, Energy Impact Partners, H.I.G. Growth Partners, CrowdStrike Falcon Fund, Osage University Partners
$265M2021-08-04	Sonoma Biotherapeutics	ARCH Venture Partners, 8VC, Casdin Capital, Mirae Asset, Lifeforce Capital, Vertex Ventures HC, Osage University Partners
$6M2021-07-26	Glyphic Biotechnologies	Cantos, CIV, Osage University Partners, Wing Venture Capital
$76M2021-05-18	Interius BioTherapeutics	Bain Capital, Cormorant Asset Management, Longwood Fund, Agent Capital, Knollwood Investment Advisory, BrightEdge, Osage University Partners
$10M2021-04-12	Hack The Box	Osage University Partners
$40M2021-03-29	Fortis Therapeutics	Osage University Partners
$80M2021-02-11	Cyteir Therapeutics	Osage University Partners
$204M2021	DICE Therapeutics	Osage University Partners
$55M2020-12-16	Atsena Therapeutics	Osage University Partners
$60M2020-10-29	Q32 Bio	Osage University Partners
$110M2020-07-07	Vor Biopharma	Osage University Partners
$—2020-01-08	Evolv Technologies	General Catalyst, DCVC, Lux Capital, Osage University Partners, SineWave Ventures
$73M2020	E-Scape Bio	Osage University Partners
$15M2020	Streetlight data	Osage University Partners
$77M2020	Escient Pharmaceuticals	Osage University Partners
$55M2019-10-22	IonQ	Samsung Catalyst Fund, Osage University Partners
$62M2019-04-24	Satsuma Pharmaceuticals	Osage University Partners
$42M2019-02-14	Vor Biopharma	Osage University Partners
$75M2019	Arrakis	Osage University Partners
$65M2019	Ribon Therapeutics	Osage University Partners
$20M2018-05-14	MediSix Therapeutics	Osage University Partners
$12M2018-04-26	Numat	Osage University Partners
$2M2018-02-27	CounterFlow	Osage University Partners
$70M2017-12-18	Aptinyx	Bain Capital, Adams Street Partners, Adage Capital Management, Longitude Capital, Agent Capital, New Leaf Venture Partners, Osage University Partners
$62M2017-12-13	Pionyr Immunotherapeutics	Osage University Partners
$10M2017-06-23	Algorithmia	Osage University Partners, Work-Bench
$16M2017-05-31	Hyalex Orthopaedics	Osage University Partners
$74M2017-02-22	PMV Pharma	Osage University Partners
$16M2017	Hyalex Orthopaedics	Osage University Partners
$22M2017	Antiva Biosciences	Osage University Partners
$37M2016-08-08	Cleave Biosciences	Osage University Partners
$65M2016-05-10	Aptinyx	Osage University Partners
$40M2015-12-22	Effector Therapeutics	Nexus Venture Partners, Osage University Partners
$10M2014-08-21	Lastline	Osage University Partners
$49M2014-04-30	Otonomy	Osage University Partners
$45M2013-09-04	Otonomy	Osage University Partners
$10M2013-04-10	Cleave Biosciences	Osage University Partners
$10M2013	Infinio	Lightspeed, Bessemer Venture Partners, Osage University Partners
$25M2012-09-24	SolarBridge Technologies	Osage University Partners
$16M2012	Millendo Therapeutics	Osage University Partners
$75M2011	Sera Prognostics	Osage University Partners
$60MUnknown date	Tessera Labs	Osage University Partners
$4MUnknown date	RapidFire.AI	Osage University Partners
$63MUnknown date	E-Scape Bio	Osage University Partners
$80MUnknown date	Dice Molecules	Osage University Partners
$34MUnknown date	Mirna Therapeutics	Osage University Partners
$35MUnknown date	Everactive	Osage University Partners
$62MUnknown date	Nocion Therapeutics	Osage University Partners
$—Unknown date	SERA Intelligence	Osage University Partners
$33MUnknown date	MC10	Osage University Partners
$50MUnknown date	ReCode Therapeutics	Osage University Partners
$75MUnknown date	AssetWatch	Osage University Partners
$110MUnknown date	Precision BioSciences	Osage University Partners
$200MUnknown date	Eridu	Osage University Partners
$55MUnknown date	Brimstone	Osage University Partners
$108M2026-04-15	Terremoto Biosciences	Osage University Partners
$—2026	Eridu AI	Catapult Ventures, Osage University Partners, TDK Ventures
$51M2023-06-08	Kate Therapeutics	Osage University Partners
$—2022-07-18	Delfi Diagnostics, Inc.	Osage University Partners
$65M2021-07-19	Ribon	Osage University Partners
$—2020-09-25	Palladio Biosciences	Osage University Partners
$4M2019-05-08	LunaPBC	ARCH Venture Partners, Bain Capital Ventures, F-Prime Capital, Bain Capital, Illumina Ventures, Osage University Partners
$30M2018-10-01	Modis Therapeutics	Osage University Partners
$63M2018-04-30	Synthorx	Osage University Partners
$2M2018-02-17	CounterFlow AI	Osage University Partners
$8M2017	KenSci, Inc.	Osage University Partners
$38M2017	Arrakis Therapeutics	Osage University Partners
$48M2016	Iconic Therapeutics	Osage University Partners
$34M2016	Cell Design Labs	Osage University Partners
$8M2015-11-03	Body Labs	Osage University Partners
$12M2015-07-24	Voxel8	ARCH Venture Partners, Autodesk, In-Q-Tel, Osage University Partners, Braemar Energy Ventures
$28M2015-02-19	Merganser Biotech	Osage University Partners
$25M2015-01-21	Jibo	CRV, Osage University Partners
$3M2014-11-03	Paracosm	boldstart ventures, Osage University Partners
$20M2014	Iconic Therapeutics	Osage University Partners
$—2012-11-13	Cardioxyl Pharmaceuticals	Osage University Partners
$37M2003	Applied Genetic Technologies Corp.	Osage University Partners
$37M2003	AGTC	Osage University Partners
$72MUnknown date	Aerovate Therapeutics	Osage University Partners
$—Unknown date	Palladio Biosciences	Osage University Partners
$63MUnknown date	Precede	Osage University Partners
$11MUnknown date	Artizan Biosciences	Osage University Partners
$50MUnknown date	ReCode	Osage University Partners
$—Unknown date	Capella Bioscience	Osage University Partners
$—Unknown date	Capella Bioscience	Osage University Partners
$1MUnknown date	Elementary Robotics	Osage University Partners
$3MUnknown date	Elementary Robotics	Osage University Partners
$32MUnknown date	Sideris Pharmaceuticals	Osage University Partners
$62MUnknown date	Nocion	Osage University Partners
$30MUnknown date	Aerie Pharmaceuticals	Osage University Partners
$4MUnknown date	Picwell	Osage University Partners

Funds4

Penn-BioNTech Innovative Therapeutics Seed Fund

OUP IV

OUP III

OUP II

Team

Co-investing

Investments